ArticleJournal of asthma and allergy2021
Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Identification of predictive factors for clinical remission and comparison of 3 definitions in Japanese patients with severe asthma treated with biologics.The journal of allergy and clinical immunology. Global · 2026Article
- Effectiveness of biological therapy in severe asthma: a retrospective real-world study.Croatian medical journal · 2025Article
- Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.Annals of medicine · 2024Observational
- Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort.Immunity, inflammation and disease · 2024Observational
- Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.Journal of asthma and allergy · 2024Article
- Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?Rheumatology advances in practice · 2024Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.Journal of clinical medicine · 2023Article
- Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study.ERJ open research · 2022Article
- Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP.BMC pulmonary medicine · 2022Article
- Severe asthma in children: An official statement from Saudi Pediatric Pulmonology Association.Saudi medical journal · 2022Article
- Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center.Biomedicines · 2022Article
- Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.Journal of asthma and allergy · 2022Article
- Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study.Journal of asthma and allergy · 2022Article
- Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.Journal of asthma and allergy · 2022Article
- Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study.Journal of asthma and allergy · 2022Article
- Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data.Journal of asthma and allergy · 2022Article
- Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE studyFrontiers in medicine · 2022Article
- Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Japan, biologic therapy was initiated for patients with severe asthma in 2009. In recent years, four biologics with different mechanisms of action have become available in the clinical setting. However, the efficacy of switching between biologics remains uncertain.
methodsTo elucidate the efficacy of switching between biologics, 97 patients were enrolled who had received any biologic therapy for severe asthma at Jikei University Hospital, Tokyo, Japan, from July 2009 to December 2020. We retrospectively examined the patient characteristics, biomarkers, pulmonary function test results, selected biologics, and efficacy.
resultsThirty-one males and 66 females received any biologics. The mean age was 53.3 years at the initiation of biologic therapy. Initially, 33, 41, 15 and eight patients received omalizumab, mepolizumab, benralizumab, and dupilumab, respectively. Among three representative indicators for biologics administration, the peripheral blood eosinophil count, serum IgE levels and fractional exhaled nitric oxide, 64% of the patients had two indicators, and 28% had three indicators. Thirty-four patients (35%) switched from the initial biologic to another, and the reasons for switching included persistent asthmatic symptoms (n=22), schedule of hospital visits (n=5), and other reasons. Thus, the treatment was effective in 11 patients after switching. In addition, two patients received combination therapy with different biologics. Eighteen patients (19%) interrupted treatment for various reasons. Regardless of whether the biologic was the initial therapy, the overall efficacy of the four biologics was 60% based on the global evaluation of treatment effectiveness.
conclusionSwitching between biologics can be a promising option for severe asthma patients in whom treatment with an initial biologic is ineffective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.